Compare Vimian Group AB with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
SEK 16,384 Million (Small Cap)
30.00
NA
0.00%
0.26
6.39%
2.07
Revenue and Profits:
Net Sales:
1,241 Million
(Quarterly Results - Mar 2026)
Net Profit:
108 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
20.72%
0%
20.72%
6 Months
-2.91%
0%
-2.91%
1 Year
-22.97%
0%
-22.97%
2 Years
-10.6%
0%
-10.6%
3 Years
-7.54%
0%
-7.54%
4 Years
-48.02%
0%
-48.02%
5 Years
0%
0%
0.0%
Vimian Group AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
59.51%
EBIT Growth (5y)
61.99%
EBIT to Interest (avg)
3.45
Debt to EBITDA (avg)
2.40
Net Debt to Equity (avg)
0.22
Sales to Capital Employed (avg)
0.43
Tax Ratio
35.21%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.21%
ROE (avg)
3.39%
Valuation key factors
Factor
Value
P/E Ratio
30
Industry P/E
Price to Book Value
1.88
EV to EBIT
18.20
EV to EBITDA
12.35
EV to Capital Employed
1.71
EV to Sales
3.43
PEG Ratio
0.75
Dividend Yield
NA
ROCE (Latest)
9.38%
ROE (Latest)
6.37%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
1,240.50
1,193.40
3.95%
Operating Profit (PBDIT) excl Other Income
347.60
351.50
-1.11%
Interest
35.30
64.60
-45.36%
Exceptional Items
-19.20
-67.90
71.72%
Consolidate Net Profit
108.00
133.60
-19.16%
Operating Profit Margin (Excl OI)
192.20%
201.80%
-0.96%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 3.95% vs 2.87% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -19.16% vs 76.72% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
4,704.10
4,286.40
9.74%
Operating Profit (PBDIT) excl Other Income
1,218.60
1,075.00
13.36%
Interest
236.90
290.50
-18.45%
Exceptional Items
-129.50
-99.50
-30.15%
Consolidate Net Profit
358.60
220.70
62.48%
Operating Profit Margin (Excl OI)
169.90%
160.90%
0.90%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 9.74% vs 12.58% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 62.48% vs 83.46% in Dec 2024
About Vimian Group AB 
Vimian Group AB
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






